News

With custom QCDR measures identified by physician leaders in The US Oncology Network, McKesson has been received approval from The Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System as a registry.

Srdan Verstovsek, MD, PhD, discusses the main reasons for his study on the use of rusfertide in patients with polycythemia vera.

Findings around trametinib as treatment of patients with an ovarian cancer subtype represent a major advance in the treatment of women with this rare ovarian and peritoneal cancer subtype, according to David Gershenson, MD.

After treatment with SurVaxM in patients with newly diagnosed glioblastoma significantly improved survival, investigators are continuing the evaluation of the agent in a phase 2b clinical trial.

In an interview with Targeted Oncology, Christopher Melani, MD, discussed the ongoing ViPOR study exploring a Bruton’s tyrosine kinase inhibitor and BCL2 inhibitor, and NF-κB survival pathway activating combination.

In an interview with Targeted Oncology, Michael A. Postow, MD, summarized the treatment landscape, provided takeaways from the most recent additions, and discussed other targets for metastatic melanoma.

In an interview with Targeted Oncology, Casey M. Cosgrove, MD, discussed the current state of biomarkers for patients with endometrial cancer and how they can be used for prognostic purposes.

AHN is utilizing a minimally-invasive surgery technique to provide better care to patients with cancer.

In its new Sunnyvale, Texas location, GenesisCare offers comprehensive patient-centered services for patients with breast cancer.

Based on data from phase 3 ECHELON-1 brentuximab vedotin in combination with chemotherapy extends survival in patients with advanced classical Hodgkin lymphoma.

Concomitant mutations, and high PD-L1 expression may be associated with an unfavorable clinical response to second-generation tyrosine kinase inhibitors in patients with ALK-rearrange non–small cell lung cancer.

Tanios S. Bekaii-Saab, MD, FACP, Richard S. Finn, MD, and William P. Harris, MD, highlight advances in research and clinical treatment of hepatocellular carcinoma over the past 10 years.

The FDA kicked off 2022 with an approval for the treatment of select patients with uveal melanoma. Here's a look back at all the FDA happenings from January 2022.

In an interview with Targeted Oncology, Nazli Dizman, MD, discussed the role of gut microbiome in cancer and speaks to her presentation given at IKCS.

An application for approval of a new dosing schedule of Rylaze has been submitted to the FDA.

The MOMENTUM trial of momelotinib showed efficacy in treating symptoms of myelofibrosis, according to a press release.

Specially trained professionals working together are required to ensure that oncologic pharmaceuticals are used safely and effectively so that patients achieve optimal clinical outcomes.

Florida Cancer Specialist & Research Institute is the leading community-based oncology practice in Florida with clinical trial opportunities made available to patients at 36 locations in the state.

In an interview with Targeted Oncology, David S. Hong, MD, discussed the mark tisotumab vedotin has made on the metastatic cervical cancer landscape thus far.

In an interview with Targeted Oncology, Yelena Ginzburg, MD, discussed the research and use of rusfertide in patients with polycythemia vera.

The label for axicabtagene ciloleucel now includes prophylactic corticosteroids use in all approved indications.

Dosing of nanatinostat and valganciclovira in a phase1b/2 clinical trial has been initiated.

Topline results from an international phase 1 study of cosibelimab are encouraging and may lead to the submission of a biologics license application to the FDA.

Ahead of its Prescription Drug User Fee Act target action date, the supplemental biologics license application for cemiplimab as treatment of metastatic cervical cancer has been withdrawn.

Investigators of the GEMSTONE-302 trial announced finding a statistically significant benefit in overall survival with sugemalimab in patients with non–small cell lung cancer.

DZD9008 for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring with EGFR exon20 insertion mutations is an investigative treatment strategy in a clinical trial.

Patients with gastrointestinal cancers are being enrolled to a phase 1/2 of pelareorep in combination with atezolizumab.

The FDA has granted a fast-track designation to the G-quadruplex stabilizer CX-5461 for BRCA1/2, PALB2, or HRD mutations in their breast or ovarian cancer.

With a partial clinical hold placed by the FDA, all studies of magrolimab plus azacitidine must halt screening and enrollment.